# The Cooper Companies, Inc. (COO) Stock Analysis: Insights into a Potential 11.58% Upside

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-insights-into-a-potential-11-58-upside/4121233373
- Published: 2026-01-05T11:17:09+00:00
- Author: Madison Wilson

The Cooper Companies, Inc. (NYSE: COO) is a prominent player in the healthcare sector,
particularly within the medical instruments and supplies industry. With a market
capitalization of $16.13 billion, Cooper stands out in the U.S. market for its innovative
contributions to eye care and women’s health products. The company operates through
two main segments: CooperVision and CooperSurgical, addressing a range of health
needs from vision correction to fertility and contraception.

Currently trading at $81.11, COO’s stock has seen a slight dip of 0.01% but remains
within its 52-week range of $64.32 to $99.45. The forward P/E ratio of 16.41 suggests
that investors are optimistic about the company’s future earnings potential, even
as traditional valuation metrics like P/E and PEG ratios are unavailable.

Cooper’s revenue growth of 4.60% signals steady progress, albeit the absence of 
net income figures leaves some questions about profitability. The company boasts
an EPS of 1.87 and a return on equity of 4.59%, which highlights its ability to 
generate earnings from shareholder investments. Meanwhile, a robust free cash flow
of $376.6 million underscores its financial health and ability to reinvest in growth
opportunities.

Dividend-seeking investors might note the absence of a dividend yield and a payout
ratio of 0%. This reflects Cooper’s strategy to reinvest earnings into business 
expansion rather than distribute profits to shareholders.

Analyst ratings reveal a positive sentiment, with 10 buy recommendations, 7 holds,
and just 1 sell. The average target price of $90.50 presents a potential upside 
of 11.58%, a compelling figure for investors considering entry or increasing positions
in COO. The target price range of $71.00 to $100.00 underscores varied analyst expectations
but indicates room for potential growth.

Technical indicators offer additional insight. COO’s 50-day moving average of $76.28
and 200-day moving average of $74.49 suggest recent price strength. An RSI of 65.71
indicates that the stock is nearing overbought territory, advising caution for momentum
investors. The MACD and signal line values of 1.70 and 2.11, respectively, provide
further technical analysis layers for those gauging entry points.

Cooper’s strategic focus on eye care through CooperVision and women’s health via
CooperSurgical positions it uniquely in the market. As it continues to innovate 
in these areas, the company’s long-term growth prospects remain appealing. Investors
should weigh the absence of specific valuation metrics against the company’s growth
potential and analyst confidence.

Overall, The Cooper Companies, Inc. presents a nuanced investment opportunity. While
challenges remain, particularly in valuation transparency and profitability metrics,
its strong market position and growth trajectory make it a stock worth watching 
closely. For those seeking exposure to the healthcare sector, COO offers a blend
of innovation, potential upside, and a foothold in essential consumer health markets.

Share on:
